Octanate (human Factor VIII/von Willebrand Factor) / Octapharma 
Welcome,         Profile    Billing    Logout  
 0 Diseases   5 Trials   5 Trials   56 News 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Octanate (human Factor VIII/von Willebrand Factor) / Octapharma
2014-005435-14: Combination treatment with DDAVP and factor VIII clotting factor concentrates in patients with mild haemophilia A. Combinatiebehandeling van DDAVP en factor VIII-concentraten in patiënten met milde hemofilie A.

Ongoing
4
60
Europe
Solution for injection/infusion, Powder and solvent for solution for injection, Minrin, Octostim, Advate, Kogenate Bayer, Helixate NexGen, ReFacto AF, Aafact, Octanate, NovoEight
Erasmus University Medical Center, ZonMw, Ferring BV, Erasmus University Medical Centre
Mild hemophilia A patients with a FVIII plasma levels above 0.05 IU/mL. Milde hemofilie A-patiënten, A clotting disorder in which clotting factor VIII is deficient, which can cause bleeding. In this study we will look at patients with the mild form. Een stollingsstoornis waarin het gehalte van stollingsfactor VIII is verlaagd. Hierdoor kunnen bloedingen veroorzaakt worden. In deze studie kijken we naar patiënten met een milde vorm., Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2019-003427-38: An international investigator trial to capture different approaches in the treatment of Hemophilia A Patients With FVIII Inhibitors

Ongoing
4
120
Europe, RoW
Octanate, Wilate, Nuwiq, Hemlibra, NovoSeven, Powder and solvent for solution for injection, Solution for injection, Octanate, Wilate, Nuwiq, Hemlibra, FEIBA NF 500 E/1000 E, NovoSeven
HZRM – Hämophilie-Zentrum Rhein Main GmbH, Octapharma AG
Inhibitor-Positive patients with Haemophilia A, Haemophilia A in patients who have developed inhibitors to any FVIII product., Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2008-008378-29: A survey on the success of inhibitor elimination using individualized concentrate selection and controlled immune tolerance induction

Checkmark ObsITI study
Jan 2013 - Jan 2013: ObsITI study
Ongoing
3
15
Europe
FACTANE 100UI/ml, KOGENATE Bayer 250 UI, HELIXATE NexGen 250 UI, REFACTO 250 UI, ADVATE 250 UI, OCTANATE 500 UI, KOGENATE Bayer 500 UI, KOGENATE Bayer 1000 UI, HELIXATE NexGen 500 UI, HELIXATE NexGen 1000 UI, REFACTO 500 UI, REFACTO 1000 UI, REFACTO 2000 UI, ADVATE 500 UI, ADVATE 1000 UI, ADVATE 1500 UI, OCTANATE 1000 UI, FACTANE 100UI/ml, KOGENATE Bayer 250 UI, HELIXATE NexGen 250 UI, REFACTO 250 UI, ADVATE 250 UI, OCTANATE 500 UI, KOGENATE Bayer 500 UI, KOGENATE Bayer 1000 UI, HELIXATE NexGen 500 UI, HELIXATE NexGen 1000 UI, REFACTO 500 UI, REFACTO 1000 UI, REFACTO 2000 UI, ADVATE 500 UI, ADVATE 1000 UI, ADVATE 1500 UI, OCTANATE 1000 UI
CHU de Saint-Etienne
patients with haemophilia A
 
 
MOTIVATE, NCT04023019: Treatment of Hemophilia A Patients With FVIII Inhibitors

Recruiting
N/A
120
Europe, US
Nuwiq, Octanate, Wilate, Emicizumab, Hemlibra, Recombinant factor VIIa (rFVIIa), NovoSeven, Activated prothrombin complex concentrate (aPCC), FEIBA
Emory University, Octapharma
Hemophilia A
12/28
06/29
Protect-NOW, NCT03695978: Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients

Recruiting
N/A
200
Europe, Canada, US, RoW
Octapharma
Haemophilia A
06/30
06/30

Download Options